Navigation Links
Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
Date:9/7/2012

Astex Pharmaceuticals, Inc (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

The collaboration combines Astex's world-renowned fragment-based drug discovery platform and epigenetic* drug development experience with the expertise in blood cancer biology at The Institute of Cancer Research (ICR) and proven success in drug discovery at the Cancer Research UK Cancer Therapeutics Unit at the ICR.

Dysregulated epigenetic mechanisms are now understood to underlie a variety of cancer types, and have been successfully targeted by the first generation of epigenetic anticancer drugs**. In some cases, specific epigenetic mutational events can be linked to disease etiology, providing an opportunity to develop highly targeted personalised medicines and associated companion diagnostics that will ultimately improve survival and reduce side effects.

"We are delighted to be entering into this new collaboration with the ICR and CRT on a key epigenetics target," said Harren Jhoti, PhD, president of Astex Pharmaceuticals. "This new partnership builds on the highly successful collaboration which Astex entered into with the ICR and CRT in 2003 on another cancer target, PKB/Akt. That collaboration led to the discovery of two clinical candidates, the first of which, AZD5363, was taken into Phase I by our partner AstraZeneca in early 2011 and the second of which, AT13148, is being prepared to be taken into Phase 1 under our development partnership with Cancer Research UK. "

Professor Paul Workman, director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, said: "ICR scientists are pioneers at unravelling blood cancer drug targets, which others have considered challenging to drug effectively. We have a very strong track record of designing drugs to attack challenging biological targets and bringing them into clinical trial, and given Astex's complementary expertise, we are very excited about the potential of this collaboration."

Dr Phil L'Huillier, director of business management at CRT, said: "Putting in place this collaboration between the Cancer Research UK-funded drug discovery team at the ICR and Astex provides a powerful route to identify drug candidates for this promising new target.

"The deal will ensure that the research programme benefits from the necessary investment to progress the research to its full potential while building on the validation and assay development work that has been carried out at the ICR and funded by Cancer Research UK and others.

"We hope that this research will lead to the development of new drugs to ultimately improve survival for cancer patients."


'/>"/>
Contact: Jane Bunce
jane.bunce@icr.ac.uk
44-207-153-5106
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
2. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
3. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
4. A North American first at the Montreal Heart Institute
5. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
6. Data release from the Allen Institute for Brain Science expands online atlas offerings
7. Los Robles Hospital’s Annual Health Fair Attended by Khanna Institute
8. Patient Experience Regional Roundtables Announced by The Beryl Institute
9. Stanford Woods Institute for the Environment announces 2012 Environmental Venture Project awards
10. Aetna Institute Designates RSC New England Center of Excellence
11. To tackle health cares thorniest problems, 400 health researchers form new U-M-based institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... ... Why does the prevalence of obesity continue to increase worldwide? Some would say lifestyle, ... cause of obesity in his new book “Body Weight Regulation.” , “Body Weight ... healthy life. Proietto said understanding the regulation of body weight and the causes of ...
(Date:12/6/2016)... Alpharetta, GA (PRWEB) , ... December 06, 2016 ... ... list of largest patient satisfaction measurement firms. The ranking is based on ... healthcare organizations such as hospitals, health systems, ambulatory surgical centers, clinically integrated networks, ...
(Date:12/6/2016)... ... December 06, 2016 , ... Public middle ... 15, 2017 to apply for a 2016/2017 California Casualty Thomas R. Brown Athletics ... Qualifying schools can receive up to $3,000. , The grant is named ...
(Date:12/6/2016)... ... December 06, 2016 , ... United ... to announce it has added CXC Solutions (CXC) as a new Strategic Partner. ... solutions are tailored to help benefits advisors reduce operating costs and generate additional ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of the ... counting and sizing services for USP 788 and 789 particulate standards compliance. The ... a response to the needs of pharmaceutical and medical device manufacturers, who are ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 Two new disaster ... in a simulated mass casualty event Tuesday at John ... The technology debuted before an audience including ... representatives from Homeland Security, Federal Law Enforcement Agencies, and ... known as HiRO (Health Integrated Rescue Operations), was developed ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... DIEGO , Dec. 6, 2016 /PRNewswire/ ... on the development of Conditionally Active Biologic ... and Beijing Sinobioway Group Company, Limited (Sinobioway) ... for development.  The specific program candidates and ... March 2015, BioAtla and Sinobioway entered into ...
Breaking Medicine Technology: